Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Divestments Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased Wages, Salaries and Other

BridgeBio Pharma (BBIO) Shares Issued (2019 - 2025)

BridgeBio Pharma's Shares Issued history spans 7 years, with the latest figure at $27.7 million for Q4 2025.

On a quarterly basis, Shares Issued rose 873.84% to $27.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $27.7 million, a 658.62% increase, with the full-year FY2025 number at $27.7 million, up 658.62% from a year prior.
Shares Issued hit $27.7 million in Q4 2025 for BridgeBio Pharma, up from -$9.7 million in the prior quarter.
Over the last five years, Shares Issued for BBIO hit a ceiling of $276.6 million in Q1 2024 and a floor of -$274.2 million in Q2 2024.
Historically, Shares Issued has averaged $15.6 million across 5 years, with a median of $2.2 million in 2023.
The widest YoY moves for Shares Issued: up 143216.06% in 2024, down 17070.05% in 2024.
Tracing BBIO's Shares Issued over 5 years: stood at -$14.3 million in 2021, then skyrocketed by 134.28% to $4.9 million in 2022, then tumbled by 109.27% to -$454000.0 in 2023, then skyrocketed by 727.31% to $2.8 million in 2024, then skyrocketed by 873.84% to $27.7 million in 2025.
Business Quant data shows Shares Issued for BBIO at $27.7 million in Q4 2025, -$9.7 million in Q3 2025, and $9.7 million in Q2 2025.